GANTRISIN PEDIATRIC
LOE ApproachingNDAORALSUSPENSION
Approved
Dec 1953
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 3h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
GANTRISIN PEDIATRIC is a pediatric oral suspension antibiotic approved in 1953 by Roche. The generic name and mechanism of action are not currently documented in available data. This legacy product serves as a foundational treatment option in pediatric infectious disease.
LOE Approaching
As a legacy product approaching loss of exclusivity, commercial teams are likely in maintenance mode with reduced staffing and focus on cost management rather than growth.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
GANTRISIN PEDIATRIC offers minimal active career growth opportunities with zero linked job openings and legacy product status. Roles available are primarily in maintenance, compliance, and operational efficiency rather than innovation or market development.
Product Manager (Maintenance)Sales Representative (Legacy Products)
Worked on GANTRISIN PEDIATRIC at Roche? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.